Stocks and Investing Stocks and Investing
Mon, November 6, 2023

Sumant Kulkarni Maintained (ACAD) at Strong Buy with Increased Target to $40 on, Nov 6th, 2023


Published on 2024-10-28 07:21:15 - WOPRAI, Sumant Kulkarni
  Print publication without navigation


Sumant Kulkarni of Canaccord Genuity, Maintained "ACADIA Pharmaceuticals Inc." (ACAD) at Strong Buy with Increased Target from $38 to $40 on, Nov 6th, 2023.

Sumant has made no other calls on ACAD in the last 4 months.



There are 10 other peers that have a rating on ACAD. Out of the 10 peers that are also analyzing ACAD, 4 agree with Sumant's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Jeffrey Hung of "Morgan Stanley" Maintained at Hold with Increased Target to $31 on, Friday, November 3rd, 2023
  • Julio Romero of "JP Morgan" Maintained at Hold with Increased Target to $29 on, Monday, August 7th, 2023
  • Jay Olson of "Oppenheimer" Reiterated at Hold and Held Target at $25 on, Thursday, August 3rd, 2023
  • Neena Bitritto-Garg of "Citigroup" Maintained at Hold with Increased Target to $27 on, Friday, July 14th, 2023


These are the ratings of the 6 analyists that currently disagree with Sumant


  • Gregory Renza of "RBC Capital" Maintained at Buy with Increased Target to $33 on, Friday, November 3rd, 2023
  • Jason Butler of "JMP Securities" Maintained at Buy with Increased Target to $42 on, Friday, November 3rd, 2023
  • Ashwani Verma of "UBS" Initiated at Strong Buy and Held Target at $33 on, Tuesday, October 17th, 2023
  • Tessa Romero of "JP Morgan" Upgraded from Hold to Buy and Increased Target to $32 on, Tuesday, October 10th, 2023
  • Sarah James of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $42 on, Tuesday, August 22nd, 2023
  • Andrew Fein of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $33 on, Thursday, August 3rd, 2023
Contributing Sources